source
- FDA approves Priovant's Lisraya (brepocitinib) for rare skin disease dermatomyositisThe U.S. Food and Drug Administration has cleared the first oral targeted treatment for dermatomyositis, a rare and disabling skin disorder. The medication, brepocitinib, will be sold under the br…
- This week in charts: Biotech’s rebound is undeniableNot only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.BioPharma Dive · 3h ago↗ source